Tarsus Drug Patent Portfolio
Tarsus owns 1 orange book drug protected by 6 US patents Given below is the list of Tarsus's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10835517 | Methods for treating ocular demodex using isoxazoline parasiticide formulations | 14 Dec, 2038 | Active |
| US11197847 | Isoxazoline parasiticide formulations and methods for treating blepharitis | 14 Dec, 2038 | Active |
| US11690826 | Methods for treating demodex blepharitis using lotilaner formulations | 14 Dec, 2038 | Active |
| US11690827 | Methods for treating ocular Demodex using lotilaner formulations | 14 Dec, 2038 | Active |
| US11752137 | Ophthalmic compositions for treating ocular Demodex using lotilaner formulations | 14 Dec, 2038 | Active |
| US8383659 | Isoxazoline derivatives as pesticides | 17 Jan, 2030 | Active |
Latest Legal Activities on Tarsus's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Tarsus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 14 May, 2024 | US10835517 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Sep, 2023 | US11752137 |
| Recordation of Patent eGrant | 12 Sep, 2023 | US11752137 |
| Patent eGrant Notification | 12 Sep, 2023 | US11752137 |
|
Email Notification
Critical
| 12 Sep, 2023 | US11752137 |
| Mail Patent eGrant Notification | 12 Sep, 2023 | US11752137 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Sep, 2023 | US11752137 |
|
Email Notification
Critical
| 24 Aug, 2023 | US11752137 |
|
Issue Notification Mailed
Critical
| 23 Aug, 2023 | US11752137 |
|
Application Is Considered Ready for Issue
Critical
| 27 Jul, 2023 | US11752137 |
| Dispatch to FDC | 27 Jul, 2023 | US11752137 |
| Response to Reasons for Allowance | 19 Jul, 2023 | US11752137 |
|
Issue Fee Payment Verified
Critical
| 19 Jul, 2023 | US11752137 |
|
Issue Fee Payment Received
Critical
| 19 Jul, 2023 | US11752137 |
|
Email Notification
Critical
| 06 Jul, 2023 | US11690826 |
Tarsus's Family Patents
Tarsus Drug List
Given below is the complete list of Tarsus's drugs and the patents protecting them.
1. Xdemvy
Xdemvy is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10835517 | Methods for treating ocular demodex using isoxazoline parasiticide formulations |
14 Dec, 2038
(13 years from now)
| Active |
| US11197847 | Isoxazoline parasiticide formulations and methods for treating blepharitis |
14 Dec, 2038
(13 years from now)
| Active |
| US11690826 | Methods for treating demodex blepharitis using lotilaner formulations |
14 Dec, 2038
(13 years from now)
| Active |
| US11690827 | Methods for treating ocular Demodex using lotilaner formulations |
14 Dec, 2038
(13 years from now)
| Active |
| US11752137 | Ophthalmic compositions for treating ocular Demodex using lotilaner formulations |
14 Dec, 2038
(13 years from now)
| Active |
| US8383659 | Isoxazoline derivatives as pesticides |
17 Jan, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xdemvy's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List